Rapid Briefs
VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.
Filtered signal trail
Daniel Cressy’s story is a powerful glimpse into the real-world era of gene therapy. It is also a reminder that access may become the next frontier.
Why now
A patient-level milestone is moving gene therapy from approval news into real-world care in Louisiana.
Regenxbio says FDA no longer requires additional studies before reviewing Navsunli/RGX-121 for accelerated approval, a potentially important rare-disease regulatory signal.
Why now
FDA has reopened a filing path after the program’s regulatory outlook had narrowed.
A new FDA draft guidance and a series of recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
